Lankenau Institute for Medical Research (LIMR), the research division of Main Line Health, will manage and commercialize several of its biomedical and health care inventions through a recently initiated agreement with the Office of Innovation at Thomas Jefferson University (Jefferson).
In addition to conducting biomedical research, LIMR’s resident faculty develop new biopharmaceutical and medical device technologies, particularly in the areas of cancer prevention, prognosis and treatment. Jefferson will assist LIMR in the licensing and commercialization of its growing patent portfolio.
“We’re excited to work with the innovation and technology-transfer experts at Jefferson to help us license selected parts of our portfolio of inventions to the biotechnology and pharmaceutical industries,” said George Prendergast, PhD, president and CEO of LIMR. “In recent years, we have expanded the number of unique technologies developed by our faculty. We look forward to working with our Jefferson colleagues to find partners to help us further develop those innovations so that they can progress to a clinic setting.”
Jefferson has licensed more than 100 inventions and started more than 25 new ventures that have gone on to raise investments of well over $200M to date. Ranked the fifth most innovative university in the North Region by U.S. News & World Report in 2018, Jefferson is considered a national leader in the development and translation of novel medical technology.
“Jefferson is honored to have been selected to partner with LIMR on the translation of its world-class medical research and innovations, and we are very much looking forward to this partnership,” said Dr. Rose Ritts, chief innovation officer and executive vice president of innovation at Jefferson.
The full list of LIMR-developed IP and technologies available for licensing is posted on the LIMR website at mainlinehealth.org/limrtech.
About Main Line Health
Founded in 1985,Main Line Health is a not-for-profit health system serving portions of Philadelphia and its western suburbs. Main Line Health’s commitment—to deliver advanced medicine to treat and cure disease while also playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to keep our community and ourselves well ahead. A team of more than 10,000 employees and 2,000 physicians care for patients throughout the Main Line Health system.
At Main Line Health’s core are four of the region’s most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation’s recognized facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.
Main Line Health also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton, King of Prussia and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare,one of the region’s largest multispecialty physician networks.
Main Line Health is the recipient of numerous awards for quality care and service, including System Magnet® designation, the nation’s highest distinction for nursing excellence and the Mid-Atlantic Alliance for Performance Excellence (MAAPE) Excellence Award. Main Line Health is committed to creating an environment of diversity, respect and inclusion and has proudly embraced the American Hospital Association’s #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education and research to help our community stay healthy.
About Lankenau Institute for Medical Research
Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center and is part of Main Line Health. Founded in 1927, LIMR’s mission is to improve human health and well-being. Faculty and staff are devoted to advancing innovative new approaches to formidable medical challenges, including cancer, cardiovascular disease, gastrointestinal disorders and autoimmune diseases, such as diabetes and arthritis. LIMR’s principal investigators conduct basic, preclinical and translational research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.